On this page
What should a rolling-review request and schedule contain?
Tie the proposed NDA/BLA portions to the designation, indication and preliminary FDA discussions. Define each reviewable unit, final content, dependencies and submission date, then retain FDA’s agreement and later changes. Keep a cumulative completion record: designation, receipt of an early portion and notification of a complete application are different events.
Before you begin
Rolling submission of NDA/BLA portions in the Fast Track or Breakthrough Therapy context described by FDA’s expedited-program guidance. It is not permission to submit uncontrolled drafts.
What you will prepare: A proposed portion-by-portion plan, evidence of FDA agreement and a controlled completion record.
Establish eligibility and discuss the plan with FDA
Appendix 2 describes preliminary agency agreement, usually discussed at the pre-NDA/pre-BLA meeting or earlier for Breakthrough Therapy products. Discuss the effectiveness evidence, proposed portions and schedule. A designation alone does not establish agreement to accept the particular rolling plan.
The request for submission of portions is sent as an IND amendment with Form 1571 and clearly identified as that request. Reconcile the existing designation, indication and agency discussions. FDA responds to the request and changes to an agreement by letter; retain those actual decisions rather than treating a project schedule as an agreed plan.
Make each portion genuinely reviewable
Use a table with portion, included documents, finalization criteria, proposed date, dependencies, known updates and owner. FDA generally accepts complete sections ready to be included in a complete application, although it may agree to less than a full section when that forms a useful reviewable unit. The guidance says not to submit drafts as rolling portions.
Distinguish a final report that later needs an amendment from an unfinished draft. Explain any proposed incomplete section and obtain agreement on its boundaries. Coordinate applicable user fees and current submission mechanics separately; a planned portion does not automatically start review, and acceptance does not guarantee immediate review scheduling.
Control final completion and the review-clock claim
The guidance states that the review clock does not begin until the applicant informs FDA that the complete NDA/BLA has been submitted. Maintain a cumulative inventory, reconcile replacements and open gaps, and identify the submission that establishes completeness. Use the supported technical format and actual FDA correspondence to control regulatory-activity metadata.
Fictional exercise: the plan labels CMC “complete” while final manufacturing information remains unresolved. Either finish the portion or discuss a specifically bounded reviewable unit with FDA; do not use a favorable title to conceal the gap. If the last clinical component is delayed, update the agreed schedule and avoid advertising the original date as the review-clock start.
Track accepted portions through final application reconciliation
Use a portion ledger that continues after the first submission. The ledger is an internal control; it does not replace the request, agency agreement or formal amendments.
| Ledger field | Evidence to retain | Why it matters |
|---|---|---|
| Agreed boundary | Portion description and FDA response | A local folder name does not define an accepted reviewable unit |
| Finality | Final report versions and review status | Draft content is not made final by labeling it a rolling portion |
| Known omission | Missing information, justification and agreed handling | An accepted limited unit is different from an undisclosed gap |
| Submission | Actual transmission, receipt and content inventory | The planned date is not evidence of delivery |
| Replacement or update | Formal amendment and affected documents | The last portion alone may not reflect the current application |
| Completion | Reconciled complete inventory and notification to FDA | Early acceptance does not establish application completeness |
Updated-report exercise: a final report was included in an accepted portion, then a corrected analysis changes its results before the last portion is submitted. Track the formal amendment, the replaced report and every affected summary. Do not leave the early summary pointing to superseded results while calling the cumulative application complete. Appendix 2 distinguishes updates to final reports from submitting drafts in the first place.
For a proposed incomplete section, specify the missing information and why the supplied final material would still support a meaningful review. FDA may agree to a useful reviewable unit at its discretion; the sponsor cannot create that agreement by changing the section title. Record the exact boundary and downstream reconciliation work.
Keep acceptance of a portion, actual commencement of review and the application review clock distinct. Appendix 2 states that accepting a portion does not necessarily mean FDA starts reviewing it immediately, and that the clock does not begin until the applicant informs FDA the complete application was submitted. That condition is not a universal calendar for every application program; use the applicable current review framework and actual correspondence. Handle applicable fee requirements through the current process without copying historical amounts or assuming a designation waives fees.
Reconcile the request with Form 1571 and the pre-submission meeting package. Use Fast Track correspondence when changes to the designated program affect the plan.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does Fast Track designation automatically approve a rolling-submission schedule?
No. FDA’s expedited-program guidance describes a separate proposal and agreement addressing the evidence, portions and timing. Preserve the actual agency response for the relevant indication. A designation letter or internal milestone schedule is not evidence that FDA agreed to accept those particular portions on those dates.
Can a rolling portion contain a draft report that will be finalized later?
The guidance says drafts should not be submitted as rolling portions. A final report that later needs updating is different: submit the revised information through a formal amendment. Identify document maturity and known omissions accurately, and obtain FDA agreement where less than a complete section is proposed.
Does acceptance of the first portion mean FDA has started its review clock?
No. Acceptance of a portion, the start of actual review work and the application review clock are distinct. Appendix 2 explains that review may not commence immediately and that the clock does not begin before the applicant notifies FDA that the complete application was submitted. Apply the relevant current program thereafter.
What should happen when an agreed rolling-review date changes?
Assess the affected portions and dependencies, then communicate the revised proposal to FDA and retain its response. The guidance describes agency letters for changes to an agreement. Update the cumulative inventory and completion plan so a superseded target is not reported as an actual submission or clock-start date.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
Expedited Programs for Serious Conditions: Drugs and Biologics ↗Final May 2014; Fast Track §§V, IX and Appendices 1–2. PDF reopened September 22, 2026; not used to freeze unrelated accelerated-approval policy.
Technical specification
FDA eCTD v4.0 Technical Conformance Guide ↗Version 1.5, June 2026; §§2.3 and 3.1. Exact cover and revision history checked September 22, 2026. Version-specific technical recommendations.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.7.3. A heading identifies placement, not mandatory applicability.